Mesothelioma Patients with a Second Cancer
Researchers in Italy looked at patients with pleural mesothelioma to see if having a second cancer affected how long they lived. They found that having a second cancer did not make a big difference in survival for most patients, but for those with a certain type of mesothelioma, it did make things worse. Factors for Multiple Types of Cancer Mesothelioma is a type of cancer that starts in the lining of organs, usually the lungs or abdomen. Most cases are caused by being exposed to asbestos. However, some people may have certain genes that make them more likely to get mesothelioma. People who have a specific gene mutation called BAP1 are more likely to get mesothelioma. They could also be … Continue reading Mesothelioma Patients with a Second Cancer
BAP1 Not the Only Gene to Raise Mesothelioma Risk
A new study is further evidence that a mutation on the BAP1 gene is not the only genetic anomaly to raise mesothelioma risk. Scientists at Philadelphia’s Fox Chase Cancer Center along with a team of international researchers recently published a study of 13 malignant mesothelioma patients. All of these patients had close relatives who also had cancer. This suggested that something in their genetic makeup might raise mesothelioma risk. Previous research suggests one gene that makes people more susceptible to mesothelioma is BAP1. People with a mutation on this gene are more likely to receive a mesothelioma diagnosis. They are also more susceptible to several other conditions. But the people in the new study were chosen because none of them … Continue reading BAP1 Not the Only Gene to Raise Mesothelioma Risk
Chemoresistance in Mesothelioma: The Role of Genetics
A team of Swiss and German researchers have a theory about why so many mesothelioma patients experience chemoresistance. Chemotherapy is the standard first-line treatment for asbestos cancer. But fewer than half of patients respond to it. The new study suggests that this may have to do with an alteration on the BAP1 gene. Medicine cannot change a person’s underlying genetics. But knowing who is likely to experience chemoresistance could help patients and doctors choose the most effective treatments. BAP1 Expression and Mesothelioma BAP1 stands for BRCA1 associated protein-1. People who have an inherited mutation of this gene produce less of the BAP1 protein. This seems to increase their risk for malignant mesothelioma and several other conditions. People with BAP1 loss … Continue reading Chemoresistance in Mesothelioma: The Role of Genetics
Breakthroughs in Mesothelioma in 2020
In spite of a global pandemic, there were some major breakthroughs in mesothelioma in 2020 that made the year a hopeful one for people fighting asbestos cancer. Malignant mesothelioma is the most serious illness caused by exposure to asbestos fibers. Mesothelioma is still not curable. But researchers have made major breakthroughs in mesothelioma diagnosis, prognosis, and treatment this year. Mesothelioma Treatment Advances Mesothelioma treatment saw the biggest breakthroughs in mesothelioma in 2020. The FDA approved the first systemic treatment for mesothelioma since 2004. That was the year that Alimta (pemetrexed) received approval. They approved a combination of the immunotherapy drugs Opdivo and Yervoy. Yervoy helps activate and proliferate T-cells. Opdivo helps existing T-cells discover the mesothelioma tumor. The patients who … Continue reading Breakthroughs in Mesothelioma in 2020
Mesothelioma and Metastatic Cancer: New Test Can Reliably Tell the Difference
Italian scientists have come up with what they believe is a nearly foolproof way to tell the difference between mesothelioma and metastatic cancer. Malignant mesothelioma is a membrane cancer caused by asbestos exposure. Metastatic cancer can start anywhere in the body. It can cause tumors on the pleural membrane that may be mistaken for mesothelioma. It is important for doctors to distinguish between these two types of malignancies. Mesothelioma and metastatic cancer are often treated differently. The Italian researchers say two biomarkers may make it easier to know which is which. The Difference Between Mesothelioma and Metastatic Cancer Metastatic cancer or metastatic carcinoma is cancer that has spread to another part of the body from where it started. This usually … Continue reading Mesothelioma and Metastatic Cancer: New Test Can Reliably Tell the Difference
Gene Targeting Slows Aggressive Form of Pleural Mesothelioma
Scientists in Vienna are developing a new treatment for a particularly aggressive form of pleural mesothelioma. This form of mesothelioma occurs in people with a genetic mutation. The mutation produces signals that fuel tumor growth. These patients typically have an even worse prognosis than other mesothelioma patients. But the Austrian team came up with a way to block activation of the mutated gene. If the gene does not send its signal, this aggressive form of pleural mesothelioma may grow more slowly. Aggression Fueled by Telomerase Malignant mesothelioma is one of the most aggressive kinds of cancer. It starts on the membranes around organs and can quickly spread to other parts of the body. By the time most people notice symptoms, … Continue reading Gene Targeting Slows Aggressive Form of Pleural Mesothelioma
BAP1 Expression Not an Independent Factor in Mesothelioma Prognosis
A new report says the prognostic role of BAP1 expression in mesothelioma is not as cut-and-dried as some studies suggest. Italian researchers analyzed the cases of 698 patients with pleural mesothelioma. The group included 60 of their own patients and another 638 from other studies. Their analysis suggests that mesothelioma prognosis has more to do with subtype than with genetic BAP1 expression. They caution doctors not to put too much stock in a patient’s BAP1 status without also considering other factors. Genetic Alterations and Mesothelioma Survival Asbestos exposure is the primary cause of mesothelioma. But not everyone who is exposed to asbestos gets cancer. This may have to do with their genetic makeup. Certain genetic alterations may make a person … Continue reading BAP1 Expression Not an Independent Factor in Mesothelioma Prognosis
Promising Data on New Mesothelioma Pill Presented at National Conference
Doctors researching a new mesothelioma pill presented research on the drug at a national virtual conference in May. The ASCO conference is one of the most important gatherings of cancer doctors in the country. This year’s online meeting gave them a chance to safely learn about new cancer research. Only the most notable research is presented at the conference. The new mesothelioma pill made the cut because research suggests it can help patients with asbestos cancer live longer. How the New Medication Works Cambridge, Massachusetts-based Epizyme makes the new mesothelioma pill, called tazemetostat (Tazverik). The oral drug blocks the protein EZH2. This protein inhibits the genes that are supposed to suppress tumor growth. Over-expression of EZH2 has been linked to … Continue reading Promising Data on New Mesothelioma Pill Presented at National Conference
Recommendations for People with a Genetic Predisposition for Mesothelioma
Cancer expects from Ohio State University have just released an updated version of their recommendations for people with a genetic predisposition for mesothelioma. These people have an inherited mutation on their BAP1 tumor suppressor gene. This mutation puts them at risk for several different types of cancer, including malignant mesothelioma. It is not possible to prevent cancer in people with this genetic risk factor. But the Ohio State doctors say awareness and screening may help extend the lives of people with a genetic predisposition for mesothelioma. BAP1 Tumor Predisposition Syndrome BAP1 stands for BRCA association protein 1. The BAP1 gene encodes for the BAP1 protein. BAP1 is one of the proteins that helps keep normal cells from turning into cancer … Continue reading Recommendations for People with a Genetic Predisposition for Mesothelioma
Possible New Drug for Mesothelioma Gets First FDA Approval
A possible new drug for mesothelioma has received FDA approval for the treatment of advanced epithelioid sarcoma. Tazemetostat (Tazverik) is an oral medication made by a company called Epizyme. It is a brand new kind of drug that blocks a protein called EZH2. Tazemetostat is in testing for several different types of cancer, including malignant mesothelioma. The recent FDA approval is an encouraging sign that it could one day be a new drug for mesothelioma. In Search of a New Drug for Mesothelioma Malignant mesothelioma is one of the most serious consequences of exposure to asbestos. Once asbestos fibers get into the lungs and other tissues, they never leave. Their presence sets up a cascade of cellular reactions that can … Continue reading Possible New Drug for Mesothelioma Gets First FDA Approval
“My Name is Paul Kraus and I Have Survived Mesothelioma for Over 20 Years.”
In 1997 I was diagnosed with mesothelioma. The doctors gave me just a few short months to live...
But here I am, 20 years later, alive and well.
I wrote a book explaining how I became the longest living mesothelioma survivor in the world.
Today, I'd like to give you a copy for free because I want more people to survive this disease.
All you have to do is click the button below now. You will receive the book within 72 hours.
I wish you good health.
Sincerely,
"It has been over four years now and I can honestly say I am doing great. I highly recommend this book because it is inspirational and educational."
Get your free copy of
“Surviving Mesothelioma” Today!